Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

4.180 +0.270 (+6.91%)
Streaming Delayed Price Updated: 2:11 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Via Benzinga
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for 4D Molecular Therapeutics
Via Benzinga
Analyst Ratings for 4D Molecular Therapeutics
Via Benzinga
4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why
4D Molecular Therapeutics (NASDAQ: FDMT) announced interim data from the 4D-710 Phase 1/2 AEROW trial for  
Via Benzinga
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
Chardan Research analyst Geulah Livshits initiated coverage on 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) with a Buy rating and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
Why Oxford Industries Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Baosheng Media Group Holdings Limited (NASDAQ: BAOS) shares climbed 91.2% to $10.81. 
Via Benzinga
Carvana, Designer Brands, REV Group And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite rising around 70 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday. 
Via Benzinga
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS